Expression of CD31/PECAM-1 (platelet endothelial cell adhesion molecule 1) by blastic plasmacytoid dendritic cell neoplasms.
Authors:
Open Access
- 1 January 2014
- journal article
- case report
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 150 (1) , 73-6
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignant neoplasm with cutaneous manifestations and a rapidly progressive clinical course. The diagnosis relies on characteristic clinicopathologic and immunopathologic features. However, the overlap of immunophenotypic features with other cancers, as well as newly discovered interpersonal and intrapersonal phenotypic variations, renders the identification of BPDCN challenging. A greater understanding of the proteins expressed by BPDCN might facilitate its recognition and provide insights into its clinical behavior. In 7 of 9 patients at 4 tertiary care institutions, immunohistochemical analysis demonstrated strong CD31/PECAM-1 (platelet endothelial cell adhesion molecule 1) expression by neoplastic cells. Combined with similar findings observed in 1 former patient, 8 of 10 cases of BPDCN were CD31/PECAM-1 positive. Expression of CD31/PECAM-1 by BPDCN adds new information about the antigenic profile of this unusual neoplasm. CD31/PECAM-1 influences multiple cell functions including adhesion, apoptosis, coagulation, host response, and protein synthesis that might affect clinical features of BPDCN such as hemorrhage, aggressive tumor growth, and resistance to therapy. Therefore, the potential role of this molecule in the tumor formation and progression of BPDCN warrants additional exploration.Keywords
This publication has 14 references indexed in Scilit:
- SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasmsBlood, 2013
- Primed T Cell Responses to Chemokines Are Regulated by the Immunoglobulin-Like Molecule CD31PLOS ONE, 2012
- Congenital blastic plasmacytoid dendritic cell neoplasmPediatric Blood & Cancer, 2011
- Evaluation of lymphangiogenic markers in Sézary syndromeLeukemia & Lymphoma, 2010
- Cutaneous Manifestations of Blastic Plasmacytoid Dendritic Cell Neoplasm—Morphologic and Phenotypic Variability in a Series of 33 PatientsAmerican Journal of Surgical Pathology, 2010
- CD4+/CD56+ Hematodermic Neoplasm (“Blastic Natural Killer Cell Lymphoma”)American Journal of Clinical Pathology, 2007
- CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of CancerJournal of Clinical Pathology, 2006
- Mechanisms of PECAM-1-mediated cytoprotection and implications for cancer cell survivalLeukemia & Lymphoma, 2005
- PECAM-1 functions as a specific and potent inhibitor of mitochondrial-dependent apoptosisBlood, 2003
- CD31 Expression in Intratumoral MacrophagesAmerican Journal of Surgical Pathology, 2001